BIOCAUSE HEILEN PHARMA released its performance for the first three quarters, with a net profit attributable to the parent company of 20.9334 million yuan, a decrease of 71.96%Zhitong·Oct 27, 2025 at 04:15 AM301211+3.74%
BIOCAUSE HEILEN PHARMA: Febuxostat tablets have obtained a drug registration certificateZhitong·Oct 21, 2025 at 02:59 AM301211+3.74%
BIOCAUSE HEILEN PHARMA: Hydrochloride of Methoxychlorpromazine has received approval for the listing application of chemical raw materialsZhitong·Sep 16, 2025 at 03:01 AM301211+3.74%
BIOCAUSE HEILEN PHARMA released its half-year performance, with a net profit attributable to the parent company of 18.5471 million yuan, a decrease of 72.92%Zhitong·Jul 31, 2025 at 03:31 AM301211+3.74%
Pharmaceutical and medical stocks continue to strengthen, with FENGYUAN PHARMACEUTICAL hitting the limit up, Hengrui Pharma rising over 7%, and Haisco, BIOCAUSE HEILEN PHARMA, Yatai pharm, and Yirui Biologics also following suitWallstreetcn·Jul 27, 2025 at 08:37 PM002653+3.88%301211+3.74%
The hepatitis concept sector has seen a short-term surgeZhitong·Jul 27, 2025 at 08:36 PM300086+2.78%002022+0.79%
Overview of A-share lock-up stock release: Lock-up stocks with a market value of 25.318 billion yuan are released todayZhitong·Jun 22, 2025 at 06:35 PM301182+9.98%688425+0.23%
BIOCAUSE HEILEN PHARMA: Ibuprofen suspension has obtained the drug registration certificateZhitong·Jun 9, 2025 at 02:58 AM301211+3.74%
BIOCAUSE HEILEN PHARMA received a drug registration certificateZhitong·Jun 5, 2025 at 03:15 AM301211+3.74%
BIOCAUSE HEILEN PHARMA: Encyclopedia Pharmaceuticals passes on-site inspection by the US FDAZhitong·May 16, 2025 at 08:05 AM301211+3.74%
Pharmaceutical stocks opened lower but rose higher, with BIOCAUSE HEILEN PHARMA and Tuoxin Pharmaceutical up over 10%, Xinhua Pharm hitting the limit up, and Hinova and Jinshi Yiyao among the top gainersZhitong·May 15, 2025 at 09:16 PM301211+3.74%301089+2.04%
The chemical pharmaceutical sector fluctuated and rose, with BIOCAUSE HEILEN PHARMA up over 10%Zhitong·May 15, 2025 at 08:53 PM000756+1.35%007190.00%
BIOCAUSE HEILEN PHARMA released its first-quarter performance, with a net profit attributable to the parent company of 10.3261 million yuan, a decrease of 72.38%Zhitong·Apr 27, 2025 at 04:01 AM301211+3.74%
BIOCAUSE HEILEN PHARMA released its 2024 annual performance, with a net profit attributable to the parent company of 91.5474 million yuan, a year-on-year decrease of 48.02%Zhitong·Apr 23, 2025 at 09:18 AM301211+3.74%
BIOCAUSE HEILEN PHARMA: Ibuprofen sustained-release capsules have obtained drug registration certificatesZhitong·Jan 20, 2025 at 02:15 AM301211+3.74%
